Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 657

1.

Jurisdictional Coordination of Integrated HIV Prevention and Patient Care Planning and Implementation.

Watts GF, Kelley D, Wilson MM, Arts S, Mims J.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219880532. doi: 10.1177/2325958219880532.

PMID:
31607234
2.

Lipid management in people with peripheral artery disease.

Golledge J, Ward NC, Watts GF.

Curr Opin Lipidol. 2019 Oct 1. doi: 10.1097/MOL.0000000000000638. [Epub ahead of print]

PMID:
31577608
3.

A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment.

Ellis KL, Hooper AJ, Pang J, Chan DC, Burnett JR, Bell DA, Schultz CJ, Moses EK, Watts GF.

Clin Genet. 2019 Sep 30. doi: 10.1111/cge.13648. [Epub ahead of print]

PMID:
31571196
4.

A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES.

Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M.

Pharmacol Res. 2019 Aug 23:104413. doi: 10.1016/j.phrs.2019.104413. [Epub ahead of print] Review.

PMID:
31449975
5.

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement.

Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG.

Curr Vasc Pharmacol. 2019;17(5):538-540. doi: 10.2174/1570161117999190517115432.

PMID:
31418346
6.

Apolipoprotein(a) Kinetics in Statin-Treated Patients with Elevated Plasma Lipoprotein(a) Concentration.

Ma L, Chan DC, Ooi EMM, Marcovina SM, Barrett PHR, Watts GF.

J Clin Endocrinol Metab. 2019 Aug 8. pii: jc.2019-01382. doi: 10.1210/jc.2019-01382. [Epub ahead of print]

PMID:
31393573
7.

Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome.

Lan NSR, Fegan PG, Rankin JM, Bell DA, Watts GF, Yeap BB.

Diabet Med. 2019 Jul 31. doi: 10.1111/dme.14095. [Epub ahead of print]

PMID:
31365761
8.

Identifying Perceptions and Preferences of the General Public Concerning Universal Screening of Children for Familial Hypercholesterolaemia.

Bowman FL, Molster CM, Lister KJ, Bauskis AT, Garton-Smith J, Vickery AW, Watts GF, Martin AC.

Public Health Genomics. 2019;22(1-2):25-35. doi: 10.1159/000501463. Epub 2019 Jul 22.

9.

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review.

Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG.

Curr Vasc Pharmacol. 2019;17(5):515-537. doi: 10.2174/1570161117666190503123911.

PMID:
31309820
10.

Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?

Chan DC, Pang J, Hooper AJ, Bell DA, Burnett JR, Watts GF.

Clin Chem. 2019 Oct;65(10):1258-1266. doi: 10.1373/clinchem.2019.306738. Epub 2019 Jul 15.

PMID:
31307996
11.

A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.

Stefanutti C, Pang J, Di Giacomo S, Wu X, Wang X, Morozzi C, Watts GF, Lin J.

J Clin Lipidol. 2019 Jul - Aug;13(4):608-617. doi: 10.1016/j.jacl.2019.05.002. Epub 2019 May 12.

12.

Response by Ward et al to Letter Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications".

Ward NC, Watts GF, Eckel RH.

Circ Res. 2019 Jun 7;124(12):e121-e122. doi: 10.1161/CIRCRESAHA.119.315233. Epub 2019 Jun 6. No abstract available.

PMID:
31170055
13.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P.

Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Review.

14.

Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy.

Warden BA, Minnier J, Watts GF, Fazio S, Shapiro MD.

J Clin Lipidol. 2019 Jul - Aug;13(4):580-585. doi: 10.1016/j.jacl.2019.04.008. Epub 2019 Apr 26.

PMID:
31130489
15.

Status of PCSK9 Monoclonal Antibodies in Australia.

Scherer DJ, Nelson AJ, O'Brien R, Kostner KM, Hare DL, Colquhoun DM, Barter PJ, Aylward P, Nicholls SJ, Watts GF.

Heart Lung Circ. 2019 Oct;28(10):1571-1579. doi: 10.1016/j.hlc.2019.04.014. Epub 2019 May 8. Review.

PMID:
31104887
16.

Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.

Pérez de Isla L, Ray KK, Watts GF, Santos RD, Alonso R, Muñiz-Grijalvo O, Diaz-Diaz JL, Badimon L, Catapano AL, Mata P.

Atherosclerosis. 2019 Jul;286:40-45. doi: 10.1016/j.atherosclerosis.2019.05.003. Epub 2019 May 4.

PMID:
31100618
17.

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry.

Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabechian D, Hughes LB, Salomon-Escoto K, Watts GFM, Jonsson AH, Rangel-Moreno J, Meednu N, Rozo C, Apruzzese W, Eisenhaure TM, Lieb DJ, Boyle DL, Mandelin AM 2nd; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Boyce BF, DiCarlo E, Gravallese EM, Gregersen PK, Moreland L, Firestein GS, Hacohen N, Nusbaum C, Lederer JA, Perlman H, Pitzalis C, Filer A, Holers VM, Bykerk VP, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S.

Nat Immunol. 2019 Jul;20(7):928-942. doi: 10.1038/s41590-019-0378-1. Epub 2019 May 6.

PMID:
31061532
18.

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text.

Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG.

Curr Vasc Pharmacol. 2019;17(5):498-514. doi: 10.2174/1570161117666190507110519.

PMID:
31060488
19.

Recent advances in synthetic pharmacotherapies for dyslipidaemias.

Sirtori CR, Yamashita S, Greco MF, Corsini A, Watts GF, Ruscica M.

Eur J Prev Cardiol. 2019 May 6:2047487319845314. doi: 10.1177/2047487319845314. [Epub ahead of print]

20.

A window into the heart of familial hypercholesterolaemia in the community.

Watts GF, Pang J.

Lancet Public Health. 2019 May;4(5):e216-e217. doi: 10.1016/S2468-2667(19)30055-6. No abstract available.

21.

What's new on therapies for elevated lipoprotein(a).

Ward NC, Schultz CJ, Watts GF.

Expert Rev Clin Pharmacol. 2019 Jun;12(6):495-499. doi: 10.1080/17512433.2019.1610391. Epub 2019 Apr 30. No abstract available.

PMID:
31002538
22.

Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.

Ward NC, Page MM, Watts GF.

Diabetes Obes Metab. 2019 Apr;21 Suppl 1:52-62. doi: 10.1111/dom.13637.

PMID:
31002454
23.

Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration.

Ma L, Chan DC, Ooi EMM, Barrett PHR, Watts GF.

Metabolism. 2019 Jul;96:8-11. doi: 10.1016/j.metabol.2019.04.010. Epub 2019 Apr 14.

PMID:
30995439
24.

To test, or not to test: that is the question for the future of lipoprotein(a).

Ellis KL, Chakraborty A, Moses EK, Watts GF.

Expert Rev Cardiovasc Ther. 2019 Apr;17(4):241-250. doi: 10.1080/14779072.2019.1596799. Epub 2019 Apr 3. Review.

PMID:
30916582
25.

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.

Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR.

J Am Heart Assoc. 2019 Apr 2;8(7):e011781. doi: 10.1161/JAHA.118.011781.

26.

PCSK9 in HIV infection: New opportunity or red herring?

Ruscica M, Watts GF, Sirtori CR.

Atherosclerosis. 2019 May;284:216-217. doi: 10.1016/j.atherosclerosis.2019.03.002. Epub 2019 Mar 9. No abstract available.

PMID:
30890266
27.

Interactions between cadherin-11 and platelet-derived growth factor receptor-alpha signaling link cell adhesion and proliferation.

Madarampalli B, Watts GFM, Panipinto PM, Nguygen HN, Brenner MB, Noss EH.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1516-1524. doi: 10.1016/j.bbadis.2019.03.001. Epub 2019 Mar 13.

PMID:
30876808
28.

Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.

Ellis KL, Pérez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P.

J Am Coll Cardiol. 2019 Mar 12;73(9):1029-1039. doi: 10.1016/j.jacc.2018.12.037.

PMID:
30846097
29.

PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies.

Ruscica M, Watts GF, Sirtori CR.

Eur J Prev Cardiol. 2019 Jun;26(9):998-1000. doi: 10.1177/2047487319833504. Epub 2019 Mar 7. No abstract available.

PMID:
30845833
30.

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, Cicero AFG; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP).

Pharmacol Res. 2019 May;143:1-16. doi: 10.1016/j.phrs.2019.02.028. Epub 2019 Mar 4. Review.

PMID:
30844537
31.

Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.

Lan NSR, Fegan PG, Yeap BB, Rankin JM, Watts GF.

Diabetes Obes Metab. 2019 Jul;21(7):1734-1736. doi: 10.1111/dom.13689. Epub 2019 Mar 28.

PMID:
30834678
32.

The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients.

Yong K, Mori T, Chew G, Beilin LJ, Puddey I, Watts GF, Irish A, Dogra G, Boudville N, Lim W.

J Ren Nutr. 2019 Sep;29(5):377-385. doi: 10.1053/j.jrn.2019.01.001. Epub 2019 Feb 22.

PMID:
30803749
33.

Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study".

Pang J, Chan DC, Hu M, Muir LA, Kwok S, Charng MJ, Florkowski CM, George PM, Lin J, Loi DD, Marais AD, Nawawi HM, Gonzalez-Santos LE, Su TC, Truong TH, Santos RD, Soran H, Tomlinson B, Yamashita S, Ademi Z, Watts GF.

J Clin Lipidol. 2019 Mar - Apr;13(2):287-300. doi: 10.1016/j.jacl.2019.01.009. Epub 2019 Jan 25.

PMID:
30797720
34.

Lymphocyte innateness defined by transcriptional states reflects a balance between proliferation and effector functions.

Gutierrez-Arcelus M, Teslovich N, Mola AR, Polidoro RB, Nathan A, Kim H, Hannes S, Slowikowski K, Watts GFM, Korsunsky I, Brenner MB, Raychaudhuri S, Brennan PJ.

Nat Commun. 2019 Feb 8;10(1):687. doi: 10.1038/s41467-019-08604-4.

35.

PCSK9 inhibition 2018: riding a new wave of coronary prevention.

Ward NC, Page MM, Watts GF.

Clin Sci (Lond). 2019 Jan 22;133(2):205-224. doi: 10.1042/CS20171300. Print 2019 Jan 31. Review.

PMID:
30670671
36.

Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies.

Pirro M, Simental-Mendía LE, Bianconi V, Watts GF, Banach M, Sahebkar A.

J Clin Med. 2019 Jan 18;8(1). pii: E118. doi: 10.3390/jcm8010118. Review.

37.

Statin Toxicity.

Ward NC, Watts GF, Eckel RH.

Circ Res. 2019 Jan 18;124(2):328-350. doi: 10.1161/CIRCRESAHA.118.312782.

PMID:
30653440
38.

Editorial: Familial Hypercholesterolaemia Registry in the MENA Region

Kolovou G, Watts GF.

Curr Vasc Pharmacol. 2019 Jan 16:1. [Epub ahead of print] No abstract available.

PMID:
30650941
39.

Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.

Santos RD, Watts GF.

Atherosclerosis. 2019 Feb;281:145-147. doi: 10.1016/j.atherosclerosis.2018.12.013. Epub 2018 Dec 22. No abstract available.

PMID:
30642653
40.

Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.

Vuorio A, Watts GF, Kovanen PT.

Atherosclerosis. 2019 Feb;281:25-30. doi: 10.1016/j.atherosclerosis.2018.11.040. Epub 2018 Dec 7. Review.

PMID:
30616181
41.

Patients with type 1 diabetes in a tertiary setting do not attain recommended lipid targets.

Lan NSR, Yeap BB, Bell DA, Watts GF, Fegan PG.

Diabetes Metab. 2019 Jan 1. pii: S1262-3636(18)30223-4. doi: 10.1016/j.diabet.2018.12.002. [Epub ahead of print] No abstract available.

PMID:
30609387
42.

Improving the detection of familial hypercholesterolaemia.

Lan NSR, Martin AC, Brett T, Watts GF, Bell DA.

Pathology. 2019 Feb;51(2):213-221. doi: 10.1016/j.pathol.2018.10.015. Epub 2018 Dec 19. Review.

PMID:
30579649
43.

Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials.

Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirotri C, Al-Rasadi K, Atkin SL.

Sci Rep. 2018 Dec 14;8(1):17887. doi: 10.1038/s41598-018-36204-7.

44.

Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.

Ma L, Waldmann E, Ooi EMM, Chan DC, Barrett HPR, Watts GF, Parhofer KG.

Eur J Clin Invest. 2019 Feb;49(2):e13053. doi: 10.1111/eci.13053. Epub 2018 Dec 13.

PMID:
30447089
45.

Dyslipidaemia in adults with type 1 diabetes-when to treat?

Lan NSR, Fegan PG, Yeap BB, Bell DA, Watts GF.

Diabetes Metab Res Rev. 2019 Jan;35(1):e3090. doi: 10.1002/dmrr.3090. Epub 2018 Nov 8.

PMID:
30339719
46.

Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease.

Watts GF, Stroes ESG.

Curr Opin Lipidol. 2018 Dec;29(6):433-435. doi: 10.1097/MOL.0000000000000560. No abstract available.

PMID:
30325759
47.

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML.

J Clin Lipidol. 2018 Nov - Dec;12(6):1358-1366. doi: 10.1016/j.jacl.2018.08.012. Epub 2018 Sep 11. Review.

PMID:
30316749
48.

Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.

Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, Mikhailidis DP, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP).

J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023-1033. doi: 10.1002/jcsm.12344. Epub 2018 Oct 11.

49.

Lipoprotein(a): lodestar for future clinical trials.

Watts GF, Boffa MB.

Lancet. 2018 Oct 13;392(10155):1281-1282. doi: 10.1016/S0140-6736(18)31922-6. Epub 2018 Oct 4. No abstract available.

PMID:
30293767
50.

Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.

Azraii AB, Ramli AS, Ismail Z, Abdul-Razak S, Mohd-Kasim NA, Ali N, Watts GF, Nawawi H.

Atherosclerosis. 2018 Oct;277:508-516. doi: 10.1016/j.atherosclerosis.2018.08.018.

PMID:
30270092

Supplemental Content

Loading ...
Support Center